Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate
- PMID: 2552904
- PMCID: PMC172638
- DOI: 10.1128/AAC.33.8.1268
Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate
Abstract
The in vitro activities of ticarcillin, piperacillin, clavulanic acid, tazobactam, ticarcillin-clavulanate, and piperacillin-tazobactam against 819 bacterial isolates were compared. The two beta-lactamase inhibitors, clavulanic acid and tazobactam, had little useful antibacterial activity but enhanced the activities of the penicillins against beta-lactamase-producing strains of Haemophilus influenzae, Branhamella catarrhalis, and methicillin-susceptible Staphylococcus aureus; all strains were susceptible to both combinations. Both enzyme inhibitors also enhanced the activities of the penicillins against most strains of Escherichia coli, Klebsiella spp., Citrobacter diversus, Proteus spp., Providencia spp., and Bacteroides spp. and against occasional strains of Citrobacter freundii, Enterobacter spp., and Serratia marcescens. Clavulanic acid frequently enhanced the activity of ticarcillin against Xanthomonas maltophilia, and tazobactam frequently enhanced the activity of piperacillin against Morganella morganii. Enhancement was observed primarily with strains relatively resistant to the penicillins. In general, clavulanic acid was more effective than tazobactam in enhancing penicillin activity against Klebsiella spp., C. diversus, X. maltophilia, and Bacteroides spp., whereas tazobactam was more effective against Escherichia coli and Proteeae. There was little or no enhancement of activity against Enterococcus faecalis, Aeromonas hydrophila, Pseudomonas aeruginosa, Pseudomonas cepacia, or Acinetobacter anitratus. Clavulanic acid occasionally antagonized the activity of ticarcillin against ticarcillin-susceptible members of the family Enterobacteriaceae, but those strains were still considered susceptible to the combination. Tazobactam never antagonized the activity of piperacillin. In a direct comparison of the activities of ticarcillin-clavulanate and piperacillin-tazobactam, the two were equally active against H. influenzae, B. catarrhalis, and S. aureus; the latter was more active against E. faecalis. For relatively susceptible strains of members of the family Enterobacteriaceae, neither combination was predictably more active than the other, but relatively resistant strains were generally more susceptible to piperacillin-tazobactam. Piperacillin-tazobactam was more active than ticarcillin-clavulanate against A. hydrophila, P. aeruginosa, and P. cepacia, similar in activity against A. anitratus, and less active against X. maltophilia and Bacteroides spp.
Similar articles
-
Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.J Antimicrob Chemother. 1990 Feb;25(2):199-208. doi: 10.1093/jac/25.2.199. J Antimicrob Chemother. 1990. PMID: 2158496
-
Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.Antimicrob Agents Chemother. 1989 Nov;33(11):1964-9. doi: 10.1128/AAC.33.11.1964. Antimicrob Agents Chemother. 1989. PMID: 2558615 Free PMC article.
-
In vitro activity of YTR 830.J Chemother. 1989 Jun;1(3):151-4. doi: 10.1080/1120009x.1989.11738883. J Chemother. 1989. PMID: 2552029
-
Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.Pharmacotherapy. 2000 Sep;20(9 Pt 2):213S-218S; discussion 224S-228S. doi: 10.1592/phco.20.14.213s.35045. Pharmacotherapy. 2000. PMID: 11001328 Review.
-
Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.J Antimicrob Chemother. 1993 Jan;31 Suppl A:29-38. doi: 10.1093/jac/31.suppl_a.29. J Antimicrob Chemother. 1993. PMID: 8383654 Review.
Cited by
-
Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.J Clin Microbiol. 2003 Jul;41(7):3339-43. doi: 10.1128/JCM.41.7.3339-3343.2003. J Clin Microbiol. 2003. PMID: 12843088 Free PMC article.
-
Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.Eur J Clin Microbiol Infect Dis. 1993 Mar;12(3):200-5. doi: 10.1007/BF01967112. Eur J Clin Microbiol Infect Dis. 1993. PMID: 8389705
-
Nonfermenting Gram-negative Bacilli other than Pseudomonas aeruginosa and Acinetobacter Spp. Causing Respiratory Tract Infections in a Tertiary Care Center.J Glob Infect Dis. 2013 Oct;5(4):144-8. doi: 10.4103/0974-777X.121996. J Glob Infect Dis. 2013. PMID: 24672175 Free PMC article.
-
Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro.Pharm Res. 1996 Jan;13(1):91-6. doi: 10.1023/a:1016085402278. Pharm Res. 1996. PMID: 8668686
-
Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients.J Clin Pharmacol. 2025 Apr;65(4):452-465. doi: 10.1002/jcph.6161. Epub 2024 Dec 3. J Clin Pharmacol. 2025. PMID: 39628093 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous